Aerosol fluoroquinolone formulations for improved pharmacokinetics
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/397
A61K-031/535
A61P-011/06
A61K-009/00
A61K-031/4375
A61K-031/47
A61K-031/538
A61K-047/02
A61K-031/536
출원번호
US-0333583
(2014-07-17)
등록번호
US-9326936
(2016-05-03)
발명자
/ 주소
Griffith, David C.
Dudley, Michael N.
Surber, Mark W.
Bostian, Keith A.
Rodny, Olga
출원인 / 주소
Raptor Pharmaceuticals, Inc.
대리인 / 주소
Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
인용정보
피인용 횟수 :
3인용 특허 :
158
초록▼
The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infection
The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
대표청구항▼
1. A pharmaceutical composition, comprising an aqueous solution consisting essentially of from about 75 mg/ml to about 150 mg/ml levofloxacin or ofloxacin and from about 160 mM to about 240 mM of a divalent or trivalent cation, wherein the solution has a pH from about 5 to about 7 and an osmolality
1. A pharmaceutical composition, comprising an aqueous solution consisting essentially of from about 75 mg/ml to about 150 mg/ml levofloxacin or ofloxacin and from about 160 mM to about 240 mM of a divalent or trivalent cation, wherein the solution has a pH from about 5 to about 7 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg. 2. The composition of claim 1, wherein the levofloxacin or ofloxacin is present at a concentration from about 80 mg/ml to about 120 mg/ml. 3. The composition of claim 1, wherein the solution consists essentially of from about 90 mg/ml to about 110 mg/ml levofloxacin and from about 180 mM to about 220 mM of a divalent or trivalent cation. 4. The composition of claim 1, wherein the solution has a pH from about 6.0 to about 6.5 and an osmolality from about 350 mOsmol/kg to about 400 mOsmol/kg. 5. The composition of claim 1, wherein the solution consists of 80 mg/ml to 120 mg/ml levofloxacin and from about 160 mM to about 240 mM of a divalent or trivalent cation. 6. The composition of claim 1, wherein the divalent or trivalent cation is selected from magnesium, calcium, zinc, copper, aluminum, and iron. 7. The composition of claim 1, wherein the divalent or trivalent cation is selected from magnesium chloride, magnesium sulfate, zinc chloride, and copper chloride. 8. The composition of claim 1, wherein the aqueous solution lacks a conventional pharmaceutical carrier or excipient selected from the group consisting of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, and magnesium carbonate. 9. A pharmaceutical composition comprising an aqueous solution consisting essentially of from about 80 mg/ml to about 120 mg/ml levofloxacin or ofloxacin and from about 175 mM to about 225 mM of a divalent or trivalent cation selected from the group consisting of magnesium, calcium, zinc, copper, aluminum, and iron; wherein the solution has a pH from about 5 to about 7 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg. 10. The pharmaceutical composition of claim 9, wherein the divalent or trivalent cation is magnesium. 11. The composition of claim 9, wherein the aqueous solution consists of the levofloxacin or ofloxacin and the divalent or trivalent cation. 12. The composition of claim 9, wherein the solution has a pH from about 6.0 to about 6.5 and an osmolality from about 350 mOsmol/kg to about 400 mOsmol/kg. 13. The composition of claim 9, wherein the solution consists essentially of from about 80 mg/ml to about 120 mg/ml levofloxacin and from about 175 mM to about 225 mM of a divalent or trivalent cation selected from the group consisting of magnesium, calcium, zinc, copper, aluminum, and iron. 14. A pharmaceutical composition comprising an aqueous solution consisting essentially of from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of magnesium chloride; wherein the solution has a pH from about 5 to about 7 and an osmolality from about 350 mOsmol/kg to about 400 mOsmol/kg. 15. The composition of claim 14, wherein the aqueous solution consists essentially of about 100 mg/ml of levofloxacin and about 200 mM magnesium chloride. 16. The composition of claim 14, wherein the aqueous solution has a pH from about 6.0 to about 6.5. 17. The composition of claim 14, wherein the aqueous solution consists of the levofloxacin and the magnesium chloride.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (158)
Sanchez Joseph P. (Canton MI) Trehan Ashok K. (Ann Arbor MI), 5-amino and 5-hydroxy-6-fluoroquinolones as antibacterial agents.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
James N. Schmidt CA; Jerry Grychowski ; Daniel K. Engelbreth CA; Robert Morton CA; Martin P. Foley CA, Aerosol medication delivery apparatus and system.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Hodson Peter D. (Trowell GB3) Baum Eric A. (Loughborough GB3) Smith David K. (Loughborough GB3) Kuepper Anton (Kaarst DEX) Wilby Matthew J. (Loughborough GB3), Breath actuated inhaler having an electromechanical priming mechanism.
Newell Robert E. (Pinner GB2) Rand Paul K. (Nitchin GB2) Fitzsimmons Robert A. (Barnard Castle GB2), Devices for administering medicaments to patients.
Casper, Robert A.; Leith, Frank A.; Gardner, David L.; Snow, John M.; Lyon, Zachary W.; Farrar, David S., Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament.
Mulhauser Paul (New York NY) Karg Jeffrey (Waldwick NY) Foxen Thomas (Brooklyn NY) Brooks Christopher J. (Glen Head NY), Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same.
Domagala John M. (Canton MI) Kiely John S. (Ann Arbor MI) Schroeder Mel C. (Dexter MI), Individual stereosiomers of 7-[3-(aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents.
Burns James S. (Darien CT) Marshak Daniel R. (Cold Spring Harbor NY), Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means.
Ambrosio Thomas J. ; Ashley Charles R. ; Bilanin Alan J. ; Huck Charles M. ; Kaufman Andrew E. ; Kenyon David J. ; Manthena Srinivas ; Sochon Henry R. ; Wilkinson Ken ; Yang Tsong-Toh, Inhaler for powdered medications.
Hess Joseph,CHX ; Bo Hu,CHX ; Weber Raphael,CHX ; Ortega Isabel,CHX ; Barraud Cedric,CHX ; van der Schoot Bart,CHX ; de Rooij Nicolaas Frans,CHX ; de Heij Bas,CHX, Liquid droplet spray device for an inhaler suitable for respiratory therapies.
Zoltan Bart J. (Old Tappan NJ) Laube Beth L. (Baltimore MD) Adams ; III George K. (Baltimore MD) Bow Clark F. (Newton NJ) Devito Ralph J. (Stanhope NJ) Harrington Walter (Flanders NJ) Hoffman Louis S, Medication delivery system phase two.
Smith Adrian E. ; Burr John D. ; Etter Jeffery W. ; Axford George S. ; Lyons Shirley W. ; Platz Robert M., Method and apparatus for dispersion of dry powder medicaments.
Blineau Joseph (Rennes FRX) Pommier Daniel (Mordelles FRX) Thomas Claude (Chasne sur Illet FRX), Multiplex channels for continuous flow for numerical signal.
Nowacki Christopher (Arlington Heights IL) Brisson Alfred G. (Kildeer IL) Dela-Cruz Exequiel (Arlington Heights IL), Pediatric asthmatic medication inhaler.
Arnold Klaus (Ingelheim am Rhein DEX) Grass Peter (Ingelheim am Rhein DEX) Knecht Adolf (Freiburg DEX) Roos Robert (Ingelheim am Rhein DEX) Sluke Gerhard (Ingelheim am Rhein DEX) Thieme Herbet (Ingel, Powders for inhalation.
Knight Jack V. (Houston TX) Wilson ; Jr. Samuel Z. (Houston TX), Small particle aerosol generator for treatment of respiratory disease including the lungs.
Barbachyn Michael R. (Kalamazoo MI) Brickner Steven J. (Portage MI) Hutchinson Douglas K. (Kalamazoo MI), Substituted oxazine and thiazine oxazolidinone antimicrobials.
Welsh, Michael J.; Zabner, Joseph, Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Loutit, Jeffery S.; Morgan, Elizabeth E.; Dudley, Michael N.; Griffith, David C.; Lomovskaya, Olga, Use of aerosolized levofloxacin for treating cystic fibrosis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.